Tonix Pharmaceuticals Holding (TNXP) Net Income towards Common Stockholders (2023 - 2025)
Historic Net Income towards Common Stockholders for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to -$32.0 million.
- Tonix Pharmaceuticals Holding's Net Income towards Common Stockholders fell 12521.64% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.2 million, marking a year-over-year increase of 2664.03%. This contributed to the annual value of -$130.0 million for FY2024, which is 1146.77% down from last year.
- As of Q3 2025, Tonix Pharmaceuticals Holding's Net Income towards Common Stockholders stood at -$32.0 million, which was down 12521.64% from -$28.3 million recorded in Q2 2025.
- In the past 5 years, Tonix Pharmaceuticals Holding's Net Income towards Common Stockholders ranged from a high of -$14.2 million in Q3 2024 and a low of -$78.8 million during Q2 2024
- Its 3-year average for Net Income towards Common Stockholders is -$29.2 million, with a median of -$27.3 million in 2023.
- Data for Tonix Pharmaceuticals Holding's Net Income towards Common Stockholders shows a peak YoY increase of 6411.09% (in 2025) and a maximum YoY decrease of 12521.64% (in 2025) over the last 5 years.
- Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's Net Income towards Common Stockholders stood at -$27.3 million in 2023, then increased by 19.08% to -$22.1 million in 2024, then plummeted by 44.79% to -$32.0 million in 2025.
- Its last three reported values are -$32.0 million in Q3 2025, -$28.3 million for Q2 2025, and -$16.8 million during Q1 2025.